Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
0.4071
+0.0033 (0.82%)
Oct 24, 2025, 10:19 AM EDT - Market open
Harvard Bioscience Revenue
Harvard Bioscience had revenue of $20.45M in the quarter ending June 30, 2025, a decrease of -11.46%. This brings the company's revenue in the last twelve months to $88.75M, down -12.24% year-over-year. In the year 2024, Harvard Bioscience had annual revenue of $94.14M, down -16.14%.
Revenue (ttm)
$88.75M
Revenue Growth
-12.24%
P/S Ratio
0.20
Revenue / Employee
$250,000
Employees
355
Market Cap
18.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HBIO News
- 5 weeks ago - Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States - GlobeNewsWire
- 6 weeks ago - Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors - GlobeNewsWire
- 2 months ago - Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Harvard Bioscience Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET - GlobeNewsWire
- 3 months ago - Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board - GlobeNewsWire
- 5 months ago - Harvard Bioscience Appoints John Duke to Board of Directors - GlobeNewsWire
- 5 months ago - Harvard Bioscience, Inc. (HBIO) Q1 2025 Earnings Call Transcript - Seeking Alpha